<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04964453</url>
  </required_header>
  <id_info>
    <org_study_id>1411-0012</org_study_id>
    <nct_id>NCT04964453</nct_id>
  </id_info>
  <brief_title>A Study in Healthy Men to Test How BI 474121 is Tolerated</brief_title>
  <official_title>Safety, Tolerability, and Pharmacokinetics of Single Rising Oral Doses of BI 474121 in Healthy Japanese Male Subjects (Double-blind, Randomised, Placebo-controlled, Parallel Group Design)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Safety, tolerability, and pharmacokinetics of BI 474121 will be assessed in healthy Japanese&#xD;
      male using single rising oral doses in order to provide the basis for an ongoing clinical&#xD;
      development of BI 474121 for the treatment of cognitive impairment in patients with&#xD;
      Alzheimer's Disease and schizophrenia.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 21, 2021</start_date>
  <completion_date type="Actual">November 11, 2021</completion_date>
  <primary_completion_date type="Actual">November 11, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage (%) of subjects with drug related adverse events</measure>
    <time_frame>up to 15 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC0-âˆž (area under the concentration-time curve of BI 474121 in plasma over the time interval from 0 extrapolated to infinity)</measure>
    <time_frame>up to 5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax (maximum measured concentration of BI 474121 in plasma)</measure>
    <time_frame>up to 5 days</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Dose group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 474121</intervention_name>
    <description>BI 474121</description>
    <arm_group_label>Dose group 1</arm_group_label>
    <arm_group_label>Dose group 2</arm_group_label>
    <arm_group_label>Dose group 3</arm_group_label>
    <arm_group_label>Dose group 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matching BI 474121</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male subjects according to the assessment of the investigator, as based on a&#xD;
             complete medical history including a physical examination, vital signs (blood pressure&#xD;
             (BP), pulse rate (PR)) including body temperature, 12-lead electrocardiogram (ECG),&#xD;
             and clinical laboratory tests at screening visit&#xD;
&#xD;
          -  Japanese ethnicity, according to the following criteria:&#xD;
&#xD;
               -  born in Japan, have lived outside of Japan &lt;10 years,&#xD;
&#xD;
               -  have parents and grandparents who are Japanese&#xD;
&#xD;
               -  Age of 20 to 45 years (inclusive) at screening visit&#xD;
&#xD;
          -  Body mass index (BMI) of 18.5 to 25.0 kilogram per square meter (kg/m2) (inclusive) at&#xD;
             screening visit&#xD;
&#xD;
          -  Signed and dated written informed consent prior to admission to the study, in&#xD;
             accordance with Good Clinical Practice (GCP) and local legislation&#xD;
&#xD;
          -  Subjects who agree to minimize the risk of making their partner pregnant by fulfilling&#xD;
             any of the following criteria starting from the first administration of trial&#xD;
             medication until 90 days after last administration of trial medication&#xD;
&#xD;
               -  Use of adequate contraception by any of the following methods plus condom:&#xD;
                  intrauterine device, combined oral contraceptives that started at least 2 months&#xD;
                  prior to the first drug administration.&#xD;
&#xD;
               -  Vasectomized (vasectomy at least 1 year prior to enrolment)&#xD;
&#xD;
               -  Surgical sterilization (including bilateral tubal occlusion, hysterectomy or&#xD;
                  bilateral oophorectomy) of the subject's female partner.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any finding in the medical examination (including BP, PR or ECG) deviating from normal&#xD;
             and assessed as clinically relevant by the investigator at screening visit&#xD;
&#xD;
          -  Repeated measurement of systolic blood pressure outside the range of 100 to 140 mmHg,&#xD;
             diastolic blood pressure outside the range of 50 to 90 millimetre of mercury (mmHg),&#xD;
             or pulse rate outside the range of 50 to 90 beats per minute (bpm) at screening visit&#xD;
&#xD;
          -  Any laboratory value outside the reference range that the investigator considers to be&#xD;
             of clinical relevance at screening visit&#xD;
&#xD;
          -  Any evidence of a concomitant disease assessed as clinically relevant by the&#xD;
             investigator&#xD;
&#xD;
               -  Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,&#xD;
                  immunological or hormonal disorders&#xD;
&#xD;
               -  Diseases of the central nervous system (including but not limited to any kind of&#xD;
                  seizures or stroke), and other relevant neurological or psychiatric disorders&#xD;
&#xD;
               -  Chronic or relevant acute infections including viral hepatitis, human&#xD;
                  immunodeficiency virus (HIV) and/or syphilis.&#xD;
&#xD;
          -  History of cholecystectomy or other surgery of the gastrointestinal tract that could&#xD;
             interfere with the pharmacokinetics of the trial medication (except appendectomy or&#xD;
             simple hernia repair)&#xD;
&#xD;
          -  History of relevant orthostatic hypotension, fainting spells, or blackouts&#xD;
&#xD;
          -  History of relevant allergy or hypersensitivity (including allergy to the trial&#xD;
             medication or its excipients)&#xD;
&#xD;
          -  further exclusion criteria apply&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>SOUSEIKAI Sumida Hospital</name>
      <address>
        <city>Tokyo, Sumida-ku</city>
        <zip>130-0004</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.mystudywindow.com/</url>
    <description>Related Info</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 13, 2021</study_first_submitted>
  <study_first_submitted_qc>July 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2021</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions:&#xD;
1. studies in products where Boehringer Ingelheim is not the license holder; 2. studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; 3. studies conducted in a single center or targeting rare diseases (because of limitations with anonymization). For more details refer to: https://www.mystudywindow.com/msw/datasharing</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

